• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Femasys Announces Second Quarter Financial Results for 2025

    8/8/25 4:05:00 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care
    Get the next $FEMY alert in real time by email

    -- Continued Progress on Regulatory Approvals and Global Commercialization of Fertility Portfolio --

    ATLANTA, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced its financial results for the second quarter of 2025.

    Corporate Highlights from 2Q 2025 to date

    • Announced European Union Medical Device Regulation approval of FemBloc®, the first global regulatory endorsement of our groundbreaking non-surgical permanent birth control solution
    • Secured first European order for FemBloc from Spain distribution partners for approximately $400,000
    • Announced Australian and New Zealand regulatory approvals for FemaSeed® and FemVue®, a cost-effective first step in fertility
    • Announced new Chief Commercial Officer to help drive execution and global growth
    • Announced partnership with Carolinas Fertility Institute, one of America's best fertility clinics, to offer FemaSeed in its eight locations
    • Announced pricing of underwritten public offering and concurrent private placement with gross proceeds of $4.5 million



    "Our second quarter marked several significant milestones for Femasys as we continue to secure key regulatory approvals, add partners, and strengthen our team to accelerate the commercialization of our innovative fertility portfolio across the globe," said Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys. "European approval of the entire FemBloc System announced in June marks the first global regulatory endorsement of our groundbreaking non-surgical permanent birth control solution. FemBloc is commercially available through strategic distribution partnerships in select countries in Europe beginning in Spain, who placed their initial order, and we will seek additional country approvals while continuing to enroll participants in our FDA IDE-approved late-stage pivotal trial for U.S. approval.

    "Regulatory approvals for FemaSeed in Australia and New Zealand announced in July also provide us with the opportunity to pursue meaningful commercial opportunities as we continue to grow revenue and broaden our global footprint. Our new partnership with Carolinas Fertility Institute will help us reach and support more patients earlier in their fertility journey. We look forward to building upon this momentum as we work towards transforming the fertility sector not only for patients, but also providers."

    Financial Results for Quarter Ended June 30, 2025

    • Sales increased by $187,784, or 84.8%, to $409,268 for the three months of 2025, compared to $221,484 for the three months of 2024 due to sales of FemaSeed and FemVue.
    • Research and development expenses decreased by $561,446, or 28.4%, to $1,414,429 for the three months of 2025 compared to $1,975,875 for the three months of 2024 primarily due to commercialization of development products into inventory and reduced clinical costs, partially offset by increased compensation costs.
    • Net loss was $4,585,922, or ($0.16) per basic and diluted share attributable to common stockholders, for the three-month period ended June 30, 2025, compared to a net loss of $4,684,574, or ($0.21) per basic and diluted share attributable to common stockholders, for the three-month period ended June 30, 2024.
    • Cash and cash equivalents as of June 30, 2025, was approximately $3.2 million and the Company had an accumulated deficit of approximately $137.7 million. The Company expects, based on its current operating plan, our current cash and cash equivalents will be sufficient to fund its ongoing operations into early fourth quarter of 2025.



    Financial Results for Six Months Ended June 30, 2025

    • Sales increased by $257,908, or 52.4%, to $750,532 for the six months of 2025, compared to $492,624 for the six months of 2024 due to sales of FemaSeed and FemVue.
    • Research and development expenses increased by $636,295, or 17.0%, to $4,382,901 for the six months of 2025 compared to $3,746,606 for the six months of 2024 primarily due to increased compensation and regulatory costs, partially offset by reduced material and development costs and clinical costs.
    • Net loss was $10,482,761, or ($0.39) per basic and diluted share attributable to common stockholders, for the six-month period ended June 30, 2025, compared to a net loss of $8,284,084, or ($0.38) per basic and diluted share attributable to common stockholders, for the same period ended June 30, 2024.



    For more information, please refer to the Company's Form 10-Q filed August 8, 2025, which can be accessed on the SEC website.



     
    FEMASYS INC.
    Condensed Balance Sheets
    (unaudited)
           
    Assets June 30,

    2025
     December 31,

    2024
    Current assets:    
     Cash and cash equivalents$3,218,067  3,451,761 
     Accounts receivable, net 254,584  488,373 
     Inventory 5,232,738  3,046,323 
     Prepaid and other current assets 1,045,591  1,035,993 
      Total current assets 9,750,980  8,022,450 
    Property and equipment, at cost:    
     Leasehold improvements 1,238,886  1,238,886 
     Office equipment 68,530  60,921 
     Furniture and fixtures 417,876  417,876 
     Machinery and equipment 3,211,109  2,856,740 
     Construction in progress 548,426  762,445 
        5,484,827  5,336,868 
    Less accumulated depreciation (3,884,964) (3,740,769)
      Net property and equipment 1,599,863  1,596,099 
    Long-term assets:    
     Lease right-of-use assets, net 1,544,724  1,805,543 
     Intangible assets, net of accumulated amortization 55,638  65,918 
     Other long-term assets 829,204  954,992 
      Total long-term assets 2,429,566  2,826,453 
      Total assets$13,780,409  12,445,002 
          
    (continued)    
           



    FEMASYS INC.
    Condensed Balance Sheets
    (unaudited)
     
    Liabilities and Stockholders' Equity  June 30,

    2025
     December 31,

    2024
    Current liabilities:    
     Accounts payable$3,263,584  1,419,044 
     Accrued expenses 1,052,752  1,151,049 
     Convertible notes payable, net (including related parties) 6,080,813  5,406,228 
     Clinical holdback – current portion 63,990  88,581 
     Lease liabilities – current portion 502,468  517,967 
       Total current liabilities 10,963,607  8,582,869 
    Long-term liabilities:    
     Clinical holdback – long-term portion 40,348  39,611 
     Lease liabilities – long-term portion 1,269,019  1,518,100 
       Total long-term liabilities 1,309,367  1,557,711 
       Total liabilities 12,272,974  10,140,580 
    Commitments and contingencies    
    Stockholders' equity:    
     Common stock, $.001 par, 200,000,000 authorized,    
      32,692,630 shares issued and 32,575,407 outstanding as of   
      June 30, 2025; and 23,473,149 shares issued    
      and 23,355,926 outstanding as of December 31, 2024 32,693  23,473 
     Treasury stock, 117,223 common shares (60,000) (60,000)
     Warrants 1,821,744  1,860,008 
     Additional paid-in-capital 137,394,016  127,679,198 
     Accumulated deficit (137,681,018) (127,198,257)
       Total stockholders' equity 1,507,435  2,304,422 
       Total liabilities and stockholders' equity$13,780,409  12,445,002 
            



    FEMASYS INC.

    Condensed Statements of Comprehensive Loss
    (unaudited)
         
        Three Months Ended June 30,  Six Months Ended June 30,
        2025  2024  2025  2024 
    Sales $409,268  221,484  750,532  492,624 
    Cost of sales (excluding depreciation expense) 158,171  73,125  275,437  161,657 
               
    Operating expenses:        
     Research and development 1,414,429  1,975,875  4,382,901  3,746,606 
     Sales and marketing 984,977  975,190  1,893,544  1,275,677 
     General and administrative 1,616,972  1,611,817  3,339,685  3,114,621 
     Depreciation and amortization 86,285  67,628  171,138  138,856 
      Total operating expenses 4,102,663  4,630,510  9,787,268  8,275,760 
      Loss from operations (3,851,566) (4,482,151) (9,312,173) (7,944,793)
    Other (expense) income:        
     Interest income 17,144  184,138  36,173  408,822 
     Interest expense (491,500) (388,311) (950,949) (749,863)
     Other expense (260,000) —  (260,000) — 
      Total other expense, net (734,356) (204,173) (1,174,776) (341,041)
      Loss before income taxes (4,585,922) (4,686,324) (10,486,949) (8,285,834)
     Income tax benefit —  (1,750) (4,188) (1,750)
      Net loss$(4,585,922) (4,684,574) (10,482,761) (8,284,084)
               
    Net loss attributable to common stockholders, basic and diluted$(4,585,922) (4,684,574) (10,482,761) (8,284,084)
    Net loss per share attributable to common stockholders, basic and diluted$(0.16) (0.21) (0.39) (0.38)
    Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted 28,880,704  22,215,516  27,025,277  21,995,436 
               

    About Femasys

    Femasys is a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide through its broad, patent-protected portfolio of novel, in-office therapeutic and diagnostic products. As a U.S. manufacturer with global regulatory approvals, Femasys is actively commercializing its lead product innovations in the U.S. and key international markets. Femasys' fertility portfolio includes FemaSeed® Intratubal Insemination, a groundbreaking first-step infertility treatment and FemVue®, a companion diagnostic for fallopian tube assessment. Published clinical trial data demonstrates FemaSeed is over twice as effective as traditional IUI, with a comparable safety profile, and high patient and practitioner satisfaction.1

    FemBloc® permanent birth control is the first and only non-surgical, in-office alternative to centuries-old surgical sterilization that received full regulatory approval in Europe in June of 2025. Commercialization of this highly cost-effective, convenient and significantly safer approach will be completed through strategic partnerships in select European countries. Alongside FemBloc, the FemChec®, diagnostic product provides an ultrasound-based test to confirm procedural success. Published data from initial clinical trials demonstrated compelling effectiveness, five-year safety, and high patient and practitioner satisfaction.2 For U.S. FDA approval, enrollment in the FINALE pivotal trial (NCT05977751) is on-going.

    Learn more at www.femasys.com, or follow us on X, Facebook and LinkedIn.

    References

    1Liu, J. H., Glassner, M., Gracia, C. R., Johnstone, E. B., Schnell, V. L., Thomas, M. A., L. Morrison, Lee-Sepsick, K. (2024). FemaSeed Directional Intratubal Artificial Insemination for Couples with Male-Factor or Unexplained Infertility Associated with Low Male Sperm Count. J Gynecol Reprod Med, 8(2), 01-12. doi: 10.33140/JGRM.08.02.08.

    2Liu, J. H., Blumenthal, P. D., Castaño, P. M., Chudnoff, S. C., Gawron, L. M., Johnstone, E. B., Lee-Sepsick, K. (2025). FemBloc Non-Surgical Permanent Contraception for Occlusion of the Fallopian Tubes. J Gynecol Reprod Med, 9(1), 01-12. doi: 10.33140/JGRM.09.01.05.

    Forward-Looking Statements 

    This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "pending," "intend," "believe," "suggests," "potential," "hope," or "continue" or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to obtain regulatory approvals for our FemBloc product candidate; develop and advance our current FemBloc product candidate and successfully enroll and complete the clinical trial; the ability of our clinical trial to demonstrate safety and effectiveness of our product candidate and other positive results; estimates regarding the total addressable market for our products and product candidate; our ability to commercialize our products and product candidate, our ability to establish, maintain, grow or increase sales and revenues, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.

    Contacts: 

    Investors: 

    [email protected]

    Media:

    [email protected]



    Primary Logo

    Get the next $FEMY alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FEMY

    DatePrice TargetRatingAnalyst
    7/13/2021$18.00Buy
    JonesTrading
    7/13/2021$25.00Buy
    Chardan Capital
    More analyst ratings

    $FEMY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Femasys Secures UK Regulatory Approval of FemBloc Permanent Birth Control

    --Advances European commercialization strategy following CE mark approval-- ATLANTA, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced that it received the Medicines and Healthcare products Regulatory Agency (MHRA) approval for its FemBloc Permanent Birth Control, which signifies the product has met the required standards for safety, quality, and effectiveness in the United Kingdom (UK). This marks an important milestone in the Company's efforts to expand availability of this revolutionary non-surgical permanent birth con

    8/20/25 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Femasys Announces Second Quarter Financial Results for 2025

    -- Continued Progress on Regulatory Approvals and Global Commercialization of Fertility Portfolio -- ATLANTA, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced its financial results for the second quarter of 2025. Corporate Highlights from 2Q 2025 to date Announced European Union Medical Device Regulation approval of FemBloc®, the first global regulatory endorsement of our groundbreaking non-surgical permanent birth control solutionSecured first European order for FemBloc from Spain distribution partners for app

    8/8/25 4:05:00 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion

    --Initiation of access to FemBloc, a revolutionary non-surgical permanent contraceptive, as global availability accelerates-- ATLANTA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced its first commercial entry into Europe with an order of approximately $400,000 USD for FemBloc Permanent Birth Control in Spain, the first country with an established distribution partnership. "We are proud to be executing on our mission to expand access to FemBloc, an innovative, non-surgical solution and the only advancement in permanent bir

    8/6/25 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    $FEMY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    JonesTrading initiated coverage on Femasys with a new price target

    JonesTrading initiated coverage of Femasys with a rating of Buy and set a new price target of $18.00

    7/13/21 11:41:28 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Chardan Capital initiated coverage on Femasys with a new price target

    Chardan Capital initiated coverage of Femasys with a rating of Buy and set a new price target of $25.00

    7/13/21 8:04:59 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    $FEMY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Commercial Officer Nicholas Kelley Stinson

    4 - FEMASYS INC (0001339005) (Issuer)

    7/1/25 4:57:48 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    New insider Nicholas Kelley Stinson claimed ownership of 125 shares (SEC Form 3)

    3 - FEMASYS INC (0001339005) (Issuer)

    7/1/25 4:54:34 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Silverman Joshua

    4 - FEMASYS INC (0001339005) (Issuer)

    6/27/25 5:25:24 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    $FEMY
    SEC Filings

    View All

    Femasys Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - FEMASYS INC (0001339005) (Filer)

    8/20/25 9:16:11 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    SEC Form S-1 filed by Femasys Inc.

    S-1 - FEMASYS INC (0001339005) (Filer)

    8/19/25 9:56:07 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Femasys Inc.

    10-Q - FEMASYS INC (0001339005) (Filer)

    8/8/25 4:16:34 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    $FEMY
    Leadership Updates

    Live Leadership Updates

    View All

    $FEMY
    Financials

    Live finance-specific insights

    View All

    Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth

    --New CCO to Lead U.S. Commercialization of Fertility Products, Including FemaSeed®, and Expand Strategic Global Partnerships Across Full Portfolio-- ATLANTA, June 17, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc. (NASDAQ:FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, today announced the appointment of Kelley Nicholas as Chief Commercial Officer (CCO). Ms. Nicholas will be responsible for leading the execution and optimization of Femasys' commercial strategy to drive revenue growth across its entire portfolio, with a particular focus on e

    6/17/25 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape

    ATLANTA, March 21, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical company focused on addressing the significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, invites investors to join management in a Fireside Chat with Jones Trading Analyst Catherine Novack to discuss the current treatment landscape for infertility treatment in women. Those interested in attending the event, which will be held virtually TODAY, March 21, 2024 at 1PM ET, may register here. Femasys CEO Kathy Lee-Sepsick and Chief Medical Officer James Liu, M.D. will focus on the current treatment options in the inf

    3/21/24 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer

    -- Seasoned sales and marketing executive with 25 years of experience leading public and private healthcare companies throughout various stages of commercialization will lead commercial launch of FemaSeed -- ATLANTA, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products, today announced the appointment of Richard Spector to chief commercial officer (CCO), effective February 2024. Mr. Spector has 25 years of experience spanning a contin

    2/6/24 8:30:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update

    -- Company delivers on mission to transform women's health with innovative solutions, including FemaSeed® for first-line infertility treatment and FemBloc® non-surgical permanent birth control (full system approval pending in Europe) -- ATLANTA, May 08, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces financial results for the quarter ended March 31, 2025 and provides a corporate update. Corporate Highlights from 1Q 2025 to date Announced FemBloc permanent birth control delivery syste

    5/8/25 5:01:00 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update

    -- Company expands commercial product offering with FemBloc® permanent birth control (delivery system) approval in Europe and signed partnerships for distribution in Spain -- ATLANTA, March 27, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces financial results for the year ended December 31, 2024 and provides a corporate update. Corporate Highlights from 4Q 2024 to date Announced FemBloc® permanent birth control (delivery system) approval in Europe; FemBloc blended polymer component s

    3/27/25 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update

    ATLANTA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces financial results for the quarter ended September 30, 2024 and provides a corporate update. Corporate Highlights from 3Q 2024 to date Announced partnership with Boston IVF, prominent network of fertility centers, to offer FemaSeed®Announced the onboarding of the first infertility medical clinic customers to offer FemaSeed infertility treatment to patients in California and FloridaAnnounced strategic distributi

    11/12/24 8:30:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    $FEMY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Femasys Inc.

    SC 13D - FEMASYS INC (0001339005) (Subject)

    11/22/23 4:00:15 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care